Literature DB >> 16609757

The association of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in peptic ulcer disease.

Juan Carlos Zapata-Colindres1, Sergio Zepeda-Gómez, Aldo Montaño-Loza, Edgar Vázquez-Ballesteros, José de Jesús Villalobos, Francisco Valdovinos-Andraca.   

Abstract

BACKGROUND AND AIM: Peptic ulcer disease (PUD) affects 10% of the world population. Helicobacter pylori infection and the use of a nonsteroidal anti-inflammatory drug (NSAID) are the principal factors associated with PUD. The aim of the present study was to evaluate a cohort of patients with PUD and determine the association between H pylori infection and NSAID use. PATIENTS AND METHODS: The medical charts of patients with endoscopic diagnosis of PUD were retrospectively reviewed from September 2002 to August 2003. Patients were divided into three groups according to ulcer etiology: H pylori infection (group 1); NSAID use (group 2); and combined H pylori infection and NSAID use (group 3).
RESULTS: One hundred two patients were evaluated: 36 men (35.3%) and 66 women (64.7%). Forty patients had H pylori infection, 43 had used NSAIDs and 15 had combined H pylori infection and NSAID use; four patients with ulcers secondary to malignancy were excluded. The frequency of women was significantly higher in group 2 (P=0.01). The mean age of patients in group 1 was significantly lower than in the other two groups (P=0.003). PUD developed earlier in group 3 than in group 2 (5.0+/-4.7 months versus 1.4+/-2.1 months, respectively, P=0.018). Thirty-two patients (32.7%) had bleeding peptic ulcer. Group 2 had a higher risk of bleeding peptic ulcer than the other two groups (P=0.001).
CONCLUSIONS: The development of PUD was observed earlier in the combined H pylori and NSAID group than in patients with only NSAID use. This suggests a synergic effect between the two risks factors in the development of PUD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16609757      PMCID: PMC2659905          DOI: 10.1155/2006/175217

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  24 in total

Review 1.  Helicobacter pylori infection.

Authors:  Sebastian Suerbaum; Pierre Michetti
Journal:  N Engl J Med       Date:  2002-10-10       Impact factor: 91.245

2.  Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial.

Authors:  Francis K L Chan; K F To; Justin C Y Wu; M Y Yung; W K Leung; Timothy Kwok; Y Hui; Henry L Y Chan; Cynthia S Y Chan; Elsie Hui; Jean Woo; Joseph J Y Sung
Journal:  Lancet       Date:  2002-01-05       Impact factor: 79.321

3.  Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis.

Authors:  Jia Qing Huang; Subbaramiah Sridhar; Richard H Hunt
Journal:  Lancet       Date:  2002-01-05       Impact factor: 79.321

4.  Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users.

Authors:  S Santolaria; A Lanas; R Benito; M f Pérez-Aisa; M Montoro; R Sainz
Journal:  Aliment Pharmacol Ther       Date:  1999-11       Impact factor: 8.171

Review 5.  [Peptic ulcer and Helicobacter pyrlori. Results and consequences of its eradication].

Authors:  M A Ballesteros-Amozurrutia
Journal:  Rev Gastroenterol Mex       Date:  2000 Oct-Dec

Review 6.  Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report.

Authors:  P Malfertheiner; F Mégraud; C O'Morain; A P S Hungin; R Jones; A Axon; D Y Graham; G Tytgat
Journal:  Aliment Pharmacol Ther       Date:  2002-02       Impact factor: 8.171

Review 7.  Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient.

Authors:  L Laine
Journal:  Gastroenterology       Date:  2001-02       Impact factor: 22.682

8.  [Gastropathy caused by non-steroidal anti-inflammatory agents and its association with Helicobacter pylori].

Authors:  Heriberto Rodríguez-Hernández; Janett S Jacobo-Karam; Joel O Jáquez-Quintana; Hilda G Avila-Romero; Liliana Galván-Román; Sandra C Lara-Miranda; Luis F Sánchez-Anguiano
Journal:  Rev Invest Clin       Date:  2003 May-Jun       Impact factor: 1.451

Review 9.  Review article: should NSAID/low-dose aspirin takers be tested routinely for H. pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing.

Authors:  R H Hunt; F Bazzoli
Journal:  Aliment Pharmacol Ther       Date:  2004-02       Impact factor: 8.171

10.  Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use.

Authors:  Kam Chuen Lai; Shiu Kum Lam; Kent Man Chu; Benjamin C Y Wong; Wai Mo Hui; Wayne H C Hu; George K K Lau; Wai Man Wong; Man Fung Yuen; Annie O O Chan; Ching Lung Lai; John Wong
Journal:  N Engl J Med       Date:  2002-06-27       Impact factor: 91.245

View more
  17 in total

Review 1.  Proton pump inhibitors: an update of their clinical use and pharmacokinetics.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-08-05       Impact factor: 2.953

2.  Association between vacA genotypes and the risk of duodenal ulcer: a meta-analysis.

Authors:  Bei-Bei Zhang; Yong Li; Xue-Qiang Liu; Pei-Jian Wang; Bo Yang; Dong-Lin Bian
Journal:  Mol Biol Rep       Date:  2014-07-26       Impact factor: 2.316

3.  Antiulcerogenic activity of Carica papaya seed in rats.

Authors:  Lorraine Aparecida Pinto; Kátia Wolff Cordeiro; Viviane Carrasco; Carlos Alexandre Carollo; Cláudia Andréa Lima Cardoso; Eliana Janet Sanjinez Argadoña; Karine de Cássia Freitas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-11-25       Impact factor: 3.000

4.  Fatal hemorrhage from a gastroaortic fistula secondary to gastric ulceration associated with Nissen fundoplication and nonsteroidal anti-inflammatory drug use.

Authors:  M Manduch; J P Rossiter; W T Depew; C Dale Mercer; D J Hurlbut
Journal:  Can J Gastroenterol       Date:  2008-03       Impact factor: 3.522

5.  Potential protective effects of Clostridium butyricum on experimental gastric ulcers in mice.

Authors:  Fang-Yan Wang; Jia-Ming Liu; Hai-Hua Luo; Ai-Hua Liu; Yong Jiang
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

Review 6.  Helicobacter pylori infection: new pathogenetic and clinical aspects.

Authors:  Krisztina Hagymási; Zsolt Tulassay
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

7.  Risk factors involved in patients with bleeding peptic ulcers: a case-control study.

Authors:  Sesha S Uppalapati; James D Boylan; Jill Stoltzfus
Journal:  Dig Dis Sci       Date:  2008-07-22       Impact factor: 3.199

8.  Pumpkin Oil-Based Nanostructured Lipid Carrier System for Antiulcer Effect in NSAID-Induced Gastric Ulcer Model in Rats.

Authors:  Osama A A Ahmed; Usama A Fahmy; Rana Bakhaidar; Mohamed A El-Moselhy; Mohamed A Alfaleh; Al-Shaimaa F Ahmed; Asmaa S A Hammad; Hibah Aldawsari; Nabil A Alhakamy
Journal:  Int J Nanomedicine       Date:  2020-04-15

Review 9.  Mannich bases in medicinal chemistry and drug design.

Authors:  Gheorghe Roman
Journal:  Eur J Med Chem       Date:  2014-10-30       Impact factor: 6.514

10.  Association between TNF α gene polymorphisms and the risk of duodenal ulcer: a meta-analysis.

Authors:  Bei-Bei Zhang; Xing-Zhen Liu; Jin Sun; Yan-Wei Yin; Qian-Qian Sun
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.